Date: 2014-02-12
Type of information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: e-Therapeutics
Product: ETS2101 (dexanabinol)
Action mechanism: ETS2101 (dexanabinol) is a synthetic cannabinoid identified by e-Therapeutics’ network pharmacology as a drug with potential in cancer treatment. Preclinical studies provided evidence of activity in a wide variety of cancer cell lines. Two phase I studies of ETS2101 are ongoing, one in patients with primary or secondary brain cancers and one in patients with various advanced solid tumours.
Disease: solid tumors
Therapeutic area: Cancer - Oncology
Country: UK
Trial details: The Phase I study will employ escalating doses of ETS2101 given orally in healthy subjects to evaluate the pharmacokinetics (PK) and oral bioavailability of ETS2101 in this form. The trial, which is conducted in the UK, is expected to recruit 24 healthy volunteers and is anticipated to complete in Q4 2014.
Latest
news: * On February 10, 2014, e-Therapeutics has announced that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.
The Phase I study will employ escalating doses of ETS2101 given orally in healthy subjects to evaluate the pharmacokinetics (PK) and oral bioavailability of ETS2101 in this form. The trial, which is conducted in the UK, is expected to recruit 24 healthy volunteers and is anticipated to complete in Q4 2014.
An I.V. formulation of ETS2101 is in two Phase I studies, an investigator-led study in brain cancer at the Moores Cancer Center of the University of California San Diego and a study at three UK Centers that is focused on patients with a variety of solid tumours.
